E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this trial is to demonstrate that dextromethorphan (DXM) and amantadine compared to placebo exert blood glucose (BG) lowering effects following an oral glucose tolerance test (OGTT) in male subjects with T2DM |
|
E.2.2 | Secondary objectives of the trial |
- To compare other pharmacodynamic (PD) properties (based on glucose, insulin, C-peptide and catecholamine measurements) of oral DXM and amantadine (termed: Investigational Medicinal Product – IMP) before and during an OGTT
- For dextromethorphan: to assess whether a dose-dependency of PD exists
-To compare the pharmacokinetic (PK) exposure to DXM and metabolites following an oral DXM dose for 5h post-dosing
-To assess the PK/PD relationship (based on AUCDXM and AUCglucose)
- To assess the safety after single oral dosing
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male with T2DM on a stable regimen of metformin monotherapy, between 45 and 70 years of age, with a BMI between 25 and 35 kg/m2, HbA1c between 6.5 and 8% (extremes included). |
|
E.4 | Principal exclusion criteria |
- Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis
- Current or previous treatment with insulin therapy
- Treatment with any hypoglycaemic medication other than metformin within the three months prior to screening
- Any severe medical or surgical history of conditions likely to confound study assessments or study endpoints
- Serious respiratory, serious and/or unstable coronary heart disease, congestive heart failure of New York Heart Association Class II or worse, second/third degree heart block, superior vena cava syndrome, uncontrolled hypertension, history of stroke (within the preceding 6 months) or serious peripheral vascular disease
- History of arrhythmia that is symptomatic or requires treatment
- Marked diabetic complications
- Any respiratory disease leading to respiratory insufficiency and/or depression
- Clinically significant vital signs or 12-lead ECG findings
- Clinical or laboratory evidence of hepatic dysfunction or disease
- Moderate or severe renal dysfunction defined as a calculated GFR <70 ml/min
- Uncontrolled high blood pressure
- History of relevant drug and/or food allergies or a history of severe anaphylactic reaction
- Use of concomitant medication which would confound study conduct |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary (PD) endpoint of the study is the area under the blood glucose (BG) concentration-time profile. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From 1-3 hours post-dose (i.e. from 0-2 hours after an OGTT) |
|
E.5.2 | Secondary end point(s) |
Secondary PD endpoints:
1. Area under the blood glucose concentration-time profile
2. Area under the blood glucose concentration-time profile
3. Area under the blood glucose concentration-time profile
4. maximum blood glucose excursion
5. maximum blood glucose concentration
6. time to maximum blood glucose concentration
7. Area under the plasma insulin concentration-time profile
8. Area under the plasma insulin concentration-time profile
9. Area under the plasma insulin concentration-time profile
10. Area under the plasma insulin concentration-time profile
11. Maximum plasma insulin concentration
12. Time to maximum plasma insulin concentration
13. area under the catecholamine (adrenaline, noradrenaline) concentration-time profile
14. catecholamine excursions
Secondary PK endpoints:
1. Area under the plasma DXM concentration-time profile
2. Area under the plasma DXM concentration-time profile
3. Area under the plasma HM concentration-time profile
4. Area under the plasma HM concentration-time profile
5. Area under the plasma DX concentration-time profile
6. Area under the plasma DX concentration-time profile
7. Area under the plasma MM concentration-time profile
8. Area under the plasma MM concentration-time profile |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary PD endpoints:
1. from 0-1 hour post-dose
2. from 1-5 hours post-dose
3. from 1-1.5 hours post-dose
4. after starting the OGTT
5. after an OGTT
6. after an OGTT
7. from 0-1 hour post-dose
8. from 1-1.5 hours post-dose
9. from 1-5 hours post-dose
10. from 1-3 hours post-dose
11. after an OGTT
12. after an OGTT
13. from 1-5 hours post-dose
14. from 0-1 hour post-dose
Secondary PK endpoints:
1. from 0-1 hour post-dose
2. from 1-5 hours post-dose
3. from 0-1 hour post-dose
4. from 1-5 hours post-dose
5. from 0-1 hour post-dose
6. from 1-5 hours post-dose
7. from 0-1 hour post-dose
8. from 1-5 hours post-dose
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 15 |